Sanofi-Aventis Sues Apotex Over ANDA For Eloxatin
Sanofi-Aventis has targeted Canada's Apotex Corp. in its latest effort to keep a generic version of colon cancer drug Eloxatin off the market in the United States....To view the full article, register now.
Already a subscriber? Click here to view full article